Consensus FibroGen, Inc.

Equities

FGEN

US31572Q8087

Delayed Nasdaq Other stock markets 03:59:42 2024-04-16 pm EDT			5-day change	1st Jan Change
1.295 ^USD	-1.15%		-14.57%	+45.55%

Apr. 15	Faron Pharmaceuticals reappoints former finance chief on interim basis	AN
Apr. 03	Top Midday Decliners	MT

Evolution of the average Target Price on FibroGen, Inc.

Price target over the last 5 years

History of analyst recommendation changes

bb3c55ac8a1ba29893f.0i37IdVbk8USTe74Y2G7qboGNIZJARiLifNJqZQLUKw.6k62GIIZx4t0GLnLIC6D5cN0XtU-aX35uqIl-bkzFZ6Ves1qlyr2_CV41g~bff34b6fbf64af73d6644e28284d120d

Analyst Recommendations on FibroGen, Inc.

Analyst recommendations: Hewlett Packard, Apple, Tesla, Mosaic, Rite Aid...	23-08-30
BofA Downgrades FibroGen to Underperform From Neutral, Adjusts Price Target to $2 From $4	23-08-08	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29 After Drug Fails to Meet Phase 3 Trial Goal	23-06-27	MT
BofA Securities Downgrades FibroGen to Neutral From Buy, Lowers Price Target to $4 From $29	23-06-27	MT
Goldman Sachs Adjusts FibroGen's Price Target to $2 From $16, Keeps Sell Rating	23-06-27	MT
Stifel Downgrades FibroGen to Hold From Buy, Cuts Price Target to $11 From $28	23-06-26	MT
William Blair Downgrades FibroGen to Market Perform From Outperform	23-06-26	MT
Raymond James Downgrades FibroGen to Market Perform From Outperform	23-06-26	MT
Stifel Upgrades FibroGen to Buy From Hold	23-06-02	MT
Cowen Adjusts Price Target on FibroGen to $25 From $15, Maintains Market Perform Rating	23-02-28	MT
Goldman Sachs Increases Price Target on FibroGen to $16 From $9, Maintains Sell Rating	23-02-21	MT
William Blair Upgrades FibroGen to Outperform From Market Perform	23-01-31	MT
Raymond James Upgrades FibroGen to Outperform From Market Perform, Price Target is $35	23-01-26	MT
BofA Securities Upgrades FibroGen to Buy From Neutral, Adjusts Price Target to $27 From $18	23-01-05	MT
Goldman Sachs Adjusts Price Target on FibroGen to $9 From $8, Maintains Sell Rating	22-11-08	MT
Goldman Sachs Adjusts FibroGen's Price Target to $8 from $9, Keeps Sell Rating	22-05-24	MT
Goldman Sachs Trims Price Target for FibroGen to $9 From $10, Maintains Sell Rating	22-03-01	MT
FIBROGEN : Goldman Sachs Downgrades FibroGen to Sell Rating From Neutral, Adjusts Price Target to $11 From $16	21-09-22	MT
FIBROGEN : Raymond James Upgrades FibroGen to Market Perform From Underperform	21-08-20	MT
FIBROGEN : Goldman Sachs Further Cuts FibroGen's Price Target to $16 From $22, Maintains Neutral Rating	21-08-12	MT
FIBROGEN : Jefferies Adjusts Price Target on FibroGen to $15 From $22, Maintains Hold Rating	21-08-10	MT
FIBROGEN : Goldman Sachs Adjusts Price Target on FibroGen to $22 From $24, Maintains Neutral Rating	21-08-10	MT
FIBROGEN : SVB Leerink Adjusts Price Target on FibroGen to $30 From $35, Maintains Outperform Rating	21-08-10	MT
FIBROGEN : Goldman Sachs Adjusts Price Target for FibroGen to $24 From $28, Maintains Neutral Rating	21-07-16	MT
FIBROGEN : Mizuho Adjusts FibroGen's Price Target to $18 from $32, Keeps Neutral Rating	21-07-16	MT